scholarly journals Intraurethral Catheter: Alternative Management for Urinary Retention in Patients With Benign Prostatic Hypertrophy

1995 ◽  
Vol 2 (2) ◽  
pp. 113-117
Author(s):  
Sulabha Punekar ◽  
Prem A. Ramkrishnan ◽  
Anand R. Kelkar ◽  
Jaydeep A. Date ◽  
Vasudeo R. Ridhorkar
Keyword(s):  
Urinary Retention ◽  
Peak Flow ◽  
Prostate Gland ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hypertrophy ◽  
Fluoroscopic Control ◽  
Calculus Formation ◽  
Clinically Significant

A polyurethane intraurethral catheter (IUC) was used in 27 patients with benign prostatic hypertrophy who were unfit for surgery, or were awaiting surgery. All of them had previously had a periurethral catheter inserted. The IUC was inserted with a cystoscope under fluoroscopic control. Spontaneous voiding through the IUC resumed in 25 patients (93%) in the immediate postprocedure period. At the end of 6 months follow-up, the peak flow rates and the residual volumes estimated in 22 patients were satisfactory. Immediate complications included incontinence due to distal displacement in 2 patients and hematuria in one patient; long-term complications included mild encrustation of the IUC in 2 patients and calculus formation on the IUC in 1 patient. None of the patients had clinically significant urinary tract infection. The presence of the IUC did not compromise the subsequent transurethral resection of the prostate gland. We recommend the use of an IUC for up to 6 months in patients with urinary retention who are awaiting surgery or are unfit for surgery as an alternative to an indwelling urethral catheter.

Epidemiological Findings on the Prevalence of Dysuria and Benign Prostatic Hypertrophy in 7303 Patients over 50 Years Old

1994 ◽  
Vol 61 (3) ◽  
pp. 169-178 ◽  
Author(s):  
M. Fini ◽  
G.F. Vagliani ◽  
A. Perrone ◽  
G. Salvi ◽  
G. Misuriello ◽  
...  
Keyword(s):  
Peak Flow ◽  
Prostate Gland ◽  
Benign Prostatic Hypertrophy ◽  
Urinary Symptoms ◽  
Equivalent Weight ◽  
Peak Flow Rate ◽  
Prostate Size ◽  
Clinically Significant ◽  
Definition Of ◽  
Incomplete Bladder Emptying

From April 1989 to April 1994 we performed a mass-screening for early diagnosis of prostatic carcinoma (by D.R.E.) on 7303 men aged 50-79 years. Moreover we evaluated the prevalence of obstructive urinary symptoms and clinically significant B.P.H. We found a prevalence rate of benign prostatic hyperplasia of 17.3% (1259/7303). The most commonly found were incomplete bladder emptying, dribbling and weak stream force. The prevalence of urinary symptoms rose significantly with increasing age and prostate size (evaluated also by T.R.U.S. on 480 men). We haven't found clear correlations between BPH and occupational or environmental risk factors. Despite the good knowledge about the development of pathological B.P.H., there is little agreement about the definition of the clinical patterns of the disease. For Garraway, B.P.H. is an enlargement of the prostate gland for an equivalent weight >20 g. in the presence of symptoms of urinary dysfunction and/or a urinary peak flow rate < 15 ml/s. Our study presents some correlations with Garraway's experience, making use of clinical and morphological evaluations. A correct clinical and social interpretation of the disease will be feasible only by comparing populations with similar diagnostic and therapeutical patterns.

Local Hyperthermia of the Prostate Gland for the Treatment of Benign Prostatic Hypertrophy and Urinary Retention

1990 ◽  
Vol 65 (2) ◽  
pp. 201-203 ◽  
Author(s):  
A. LINDNER ◽  
Z. BRAF ◽  
A. LEV ◽  
J. GOLOMB ◽  
Z. LEIB ◽  
...  
Keyword(s):  
Urinary Retention ◽  
Prostate Gland ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hypertrophy ◽  
Local Hyperthermia

Morbidity in long-term survivors after pancreatoduodenectomy for pancreatic adenocarcinoma.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 307-307
Author(s):  
Kathryn Tzung-Kai Chen ◽  
John Parker Hoffman
Keyword(s):  
Pancreatic Adenocarcinoma ◽  
R0 Resection ◽  
Portal Veins ◽  
Clinically Significant ◽  
Portal Venous Thrombosis ◽  
Long Term Survivors ◽  
Disease Free ◽  
Denver Shunt

307 Background: Because the focus of pancreatoduodenectomy for pancreatic adenocarcinoma is placed on disease-free and overall survival, morbidity in long-term survivors is not well described. We sought to evaluate outcomes of long-term survivors of pancreatic cancer after pancreatoduodenectomy. Methods: We identified 30 patients from our prospectively collected database of patients with pancreatic adenocarcinoma who had undergone pancreatoduodenectomy, and who were without evidence of disease with at least 40 months of follow-up. Demographics, treatment and pathologic characteristics were collected for review. Data with regards to long-term sequelae were also collected, particularly those complications requiring additional procedures and the development of metachronous cancers. Results: The median length of follow up was 83 months, with 60% of patients still alive. Half the patients were male, and the median age at diagnosis was 70 years. With regard to treatment, 80% of patients received chemoradiation, with half of these patients receiving it in the neoadjuvant setting. All patients received an R0 resection, although two patients required at least partial resection of the superior mesenteric or portal veins. Thirty-three percent of patients had N1 disease. Forty-four percent of patients did not have any significant subsequent sequelae. In the remainder, four patients (13%) developed ascites requiring repeated paracentesis or Denver shunt, with median time to development (MTD) of 63 months. Six patients (20%) developed a biliary stricture requiring stent placement (MTD 56 months), one patient developed portal venous thrombosis requiring a venous stent (MTD 52 months), and 3 patients (10%) experienced clinically significant gastric anastomotic ulcers (MTD 47 months). With regards to metachronous cancers, 2 patients developed subsequent lymphomas (MTD 92 months). Conclusions: Long-term survivors of patients who undergo pancreatoduodenectomy for pancreatic adenocarcinoma can develop significant late sequelae, which often can manifest more than three to five years after surgery. Continued follow-up and counseling is warranted.

Sign in / Sign up

Export Citation Format

Share Document